Furthermore, evidence for promoting ERS signaling as the anti-NSCLC therapy, especially activating the death effector CHOP via the PERK-ATF4 cascade, is compelling7, 31, 32. This evidence concerns the gene DDIT3 and non-small cell lung carcinoma.